Prevalence of human immunodeficiency virus (HIV) antibodies in tuberculosis patients in Lagos, Nigeria.
To establish the prevalence of HIV antibodies in patients with pulmonary tuberculosis, 536 new cases presenting with symptoms of bronchopulmonary disorders were randomly selected from the six referral chest clinics in Lagos and screened for tuberculosis and HIV infections. Sputum and serum samples were obtained from all the patients. The sputum samples were examined for acid-fast bacilli (AFB) by both microscopy and culture. The sera were screened for HIV-1 and HIV-2 antibodies by ELISA and confirmed by Western blot (WB). Of the 536 cases studied, 188 (35%) were positive for AFB while 13 (2.4%) were seropositive for HIV. Correlation between the AFB and HIV results revealed that 10 (5.3%) of the 188 AFB positives were also seropositive for HIV as compared to 3 (0.9%) in the 348 AFB negative cases. The difference in the HIV seroprevalence rates in the two groups was statistically significant (P < 0.001). The recorded higher frequency of HIV infections in the AFB positives strongly suggested some level of interaction between TB and HIV infections in Lagos. Infections with HIV-2 were more prevalent than HIV-1 in the patients with HIV and TB. No case of dual infection with HIV-1 and HIV-2 was recorded in this group of patients. However, in the 3 HIV-seropositive patients within the control group (non-tuberculosis patients), 2 (67%) were positive for both HIV-1 and HIV-2 while 1 (33%) was positive for HIV-2 only. Mycobacterium tuberculosis (70%), M. avium (20%) and M. kansasii (10%) were the mycobacteria strains isolated from the HIV/TB infected patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Idigbe
E O
EO
Bacteriology Laboratory, National Institute for Medical Research, Yaba, Lagos.
Nasidi
A
A
Anyiwo
C E
CE
Onubogu
C
C
Alabi
S
S
Okoye
R
R
Ugwu
O
O
John
E K
EK
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D015153:Blotting, Western; D016009:Chi-Square Distribution; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology; D015498:HIV-2 / Q000276:immunology; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D009549:Nigeria / Q000453:epidemiology; D010865:Pilot Projects; D011159:Population Surveillance; D016036:Seroepidemiologic Studies; D013183:Sputum / Q000382:microbiology; D014376:Tuberculosis / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D014504:Urban Health
D000914:Antibodies, Viral